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disutility may be used in cost-utility analysis to estimate treatment outcomes for 
T2DM.
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Objectives: Reimbursement agencies in Europe have questioned the benefits 
offered by rapid-acting analog insulin (RAAI) over regular human insulin (RHI) in 
type 1 diabetes (T1D). This analysis evaluates the cost-effectiveness of RAAI rela-
tive to RHI using a T1D-specific health economic model developed using recently 
published clinical data. MethOds: The PRIME Diabetes Model — a patient-level, 
discrete-event simulation — was used to evaluate health and cost outcomes in 
100,000 people with T1D in the UK setting over a 50-year time horizon. The mean 
cohort characteristics (age 35.2 years, duration of diabetes 13.7 years, HbA1c 7.4%, 
body mass index 23.8 kg/m2, and 61.3% male) and insulin doses were derived 
from a clinical trial comparing RAAI with RHI, both with basal insulin glargine. 
In the base case, RHI changed HbA1c by −0.312%, and a meta-analysis indicated 
that the additional impact of RAAI was −0.09%. Compared with RHI, the relative 
rate of hypoglycemic events with RAAI was 1.07 (non-severe daytime), 0.51 (non-
severe nocturnal), and 0.80 (severe). An annual discount rate of 3.5% was applied 
to health and cost outcomes. Results: RAAI was associated with increased qual-
ity of life, providing an extra 0.68 quality-adjusted life years (QALYs) per patient 
compared with RHI (11.54 vs. 10.86). QALY gains were driven by reduced noctur-
nal and severe hypoglycemia. Reductions in hospitalizations related to severe 
hypoglycemia also contributed to a slight survival benefit with RAAI (19.4% vs. 
18.7% at 50 years). Direct medical costs were higher with RAAI than with RHI, 
though the mean cost difference per patient was small: GBP 3,473. The incremen-
tal cost-effectiveness ratio was estimated at GBP 5,103 per QALY gained. Results 
were robust under probabilistic sensitivity analyses. cOnclusiOns: In T1D, RAAI 
is associated with beneficial patient outcomes compared with RHI and is esti-
mated to be cost-effective in the UK given generally accepted willingness-to-pay 
thresholds.
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Objectives: To evaluate the cost effectiveness and cost-utility the one-step scheme, 
recommended by the International Association of Diabetes and Pregnancy Study 
Group (IADPSG), compared with the two-step scheme, recommended by the American 
Diabetes Association (ADA) for screening and diagnosis of gestational diabetes mel-
litus in Colombia MethOds: We designed a decision tree model that compared the 
effectiveness, based on a systematic literature review, and expected costs for each 
alternative. Outcomes included correctly diagnosed cases, pre-term births and other 
obstetric complications. Utility weights, in QALYs, were derived from the literature. 
The analysis was conducted from a third-party payer perspective, considering only 
direct medical costs both for normal pregnancy and associated complications, based 
on base cases designed by an expert panel, and resource use turned into prices using 
official tariff manuals. Time frame was from gestational week 24 until one month 
after delivery. Results were subject to univariate and probabilistic sensitivity analyses. 
Costs were in 2014 Colombian pesos (1 euro = COP 2,660). Results: By using the 
one-step scheme average costs per pregnant woman were similar for the one-step 
(€ 476), or the two-step (€ 500) schemes. In terms of adverse maternal and neona-
tal outcomes, the one-step scheme shows better clinical performance and slightly 
more QALYs gained (0.06). A correct diagnosis would be reached in 921 and 853 
women per thousand, respectively. One-step scheme averted 8 pre-term births 
per thousand. The results withstood the sensitivity analyses. cOnclusiOns: 
A one-step scheme should lead to slightly lower expected costs and better clinical 
outcomes.
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Objectives: Guidelines for the management of type 1 diabetes advocate treat-
ment regimens that reduce the frequency of hypoglycaemic episodes, while 
maintaining blood glucose levels as near normal as is feasible. Therapy-related 
consequences of treatment, such as weight gain and hypoglycaemia act as a bar-
rier to optimal glycaemic control and impact the cost-effectiveness of therapies. 
This study sought to ascertain the respective contribution of changes in hypogly-
caemia, weight and glycosylated haemoglobin (HbA1c) to quality-adjusted sur-
vival among a type 1 diabetic population. MethOds: The Cardiff Type 1 Diabetes 
Model was utilised to model an EDIC-type population: age 33.3 years, 47% female, 
with baseline BMI 25.8 kg/m2, HbA1c 8.2% and duration of diabetes 12.1 years. 
Baseline hypoglycaemia rates and utility decrements associated with macro- and 
microvascular complications, hypoglycaemia and weight change were sourced 
from the published literature. Treatment related changes in symptomatic hypo-
glycaemia (±10%, 20% or 30%) and weight (±1kg, 2kg or 3kg) were applied over 
the first 6 months of treatment and quality-adjusted life years (QALYs) evalu-
domized clinical trial (Nauck et al. 2011, 52 weeks) comparing DAPA+MET vs 
SU+MET was considered to determine the proportion of patients achieving 7 clini-
cally relevant composite endpoints (CEP) including: changes in HbA1c, weight, 
hypoglycaemic events and systolic blood pressure (SBP). Additionally, it was cal-
culated the cost per patient that achieved CEP. Results: Patients treated with 
DAPA+MET showed a higher probability to achieve different CEP than SU+MET. In 
the case of CEP combining HbA1c< 7%, no hypoglycemic events and ≥ 5% weight 
loss: 96% DAPA+MET and 4% SU+MET achieved it and were approximately 22 
times more likely to achieve this CEP vs. SU+MET. In the case of CEP combining 
HbA1c< 7%, no hypoglycaemic events and ≥ 3% weight loss: 92% patients treated 
with DAPA+MET and 8% with SU+MET achieved it and the probability was 11 times 
higher with DAPA+MET. And in CEP combining HbA1creduction ≥ 0.5%, weight loss 
≥ 3% and SBP reduction ≥ 3 mmHg: 91% patients treated with DAPA+MET achieved 
it and 9% with SU+MET and the probability was 10 times higher. The cost per 
patients achieved different CEP was between € 3,058 and € 9,386 with DAPA+MET, 
whereas with SU+MET was between € 5,125and € 82,005, showing that sulfony-
lureas use could result in a achieved CEP cost per patient up to 8,7 times more 
expensive than treating patients with DAPA. cOnclusiOns: The analysis showed 
that more patients treated with DAPA+MET in comparison with SU+MET achieved 
the CEP considered after one year of treatment, and it was also associated with 
a lower cost per patient.
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Objectives: Canagliflozin, an agent that inhibits sodium glucose co-transporter 2, 
decreases glucose levels by lowering the renal threshold for glucose excretion, thereby 
increasing urinary glucose excretion (UGE). Increased UGE lowers glucose and reduces 
body weight and systolic blood pressure (SBP). In contrast, dipeptidyl peptidase-4 
inhibitors such as sitagliptin lower glucose but are not associated with weight loss 
or SBP reduction, and sulfonylureas (glimepiride) are associated with weight gain 
and hypoglycaemia risk. The objective of this analysis was to assess the treatment 
costs of canagliflozin versus glimepiride or sitagliptin in patients with type 2 diabetes 
mellitus (T2DM) inadequately controlled with metformin from the Italian National 
Health Service perspective. MethOds: Two CMAs were conducted to compare the 
mean annual direct costs of a patient with T2DM receiving canagliflozin (100 or 300 
mg) or glimepiride (5,6 mg) or sitagliptin (100 mg). Both analyses estimated 12-month 
annual patient costs. Treatment effects and adverse event rates were sourced from 
head-to-head studies (ie, direct comparisons) in dual therapy with background met-
formin in the canagliflozin Phase 3 program. In both analyses, only direct medical 
costs (eg, antihyperglycaemic and other drugs, hospitalizations after hypoglycaemic 
events, blood glucose monitoring) were considered. The analysis also included direct 
healthcare cost savings associated with weight reduction. Italian costs were sourced 
from the literature and local sources. Uncertainty was assessed by deterministic sen-
sitivity analysis. Results: Canagliflozin 100 and 300 mg showed lower expected costs 
(€ 2.785,46 and € 2.979,52, respectively) versus glimepiride (€ 3.167,90). Canagliflozin 100 
and 300 mg also showed lower expected costs (€ 2.820,05 and € 3.013,96, respectively) 
versus sitagliptin (€ 3.030,38). cOnclusiOns: This CMA showed that canagliflozin 
(100 or 300 mg) is a cost-saving strategy compared with glimepiride or sitagliptin in 
the treatment of patients with T2DM inadequately controlled with metformin from 
the perspective of the Italian National Health Service.
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Objectives: Hypoglycemia is one of the major limiting factors in the management 
of T2DM patients on insulin. Disutility for different types of hypoglycemic events 
is an important component of cost-utility analysis. The aim of this study was to 
determine disutility for mild, severe and nocturnal hypoglycemic events in T2DM 
patients receiving insulin therapy. MethOds: One thousand T2DM patients on 
insulin (mean age – 61.1 yrs; male/female – 265/735) were included in the real-
world study aimed to measure their quality of life and hypoglycemia burden. All 
the patients completed SF-36 questionnaire. To determine the utility value for each 
patient SF-6D questionnaire based on the SF-36 was used. In total, 631 patients 
recorded episodes of hypoglycemia during the last month. The patients without 
hypoglycemia and patients with mild, severe or nocturnal hypoglycemic events were 
analyzed. The average utility value for each group was calculated with adjustment 
for gender, age, comorbidities, late complications, glycosylated hemoglobin level. 
The disutility for one episode of each type of hypoglycemia was determined as 
the difference between the average utility for patients without hypoglycemia and 
average utility for patients with corresponding type of hypoglycemia. Results: The 
utility value for patients without hypoglycemia was 0.680; for patients with mild 
hypoglycemia – 0.668; for patients with severe hypoglycemia – 0.595; for patients 
with nocturnal hypoglycemic event – 0.657. Patients without hypoglycemia had the 
highest utility value whereas patients with severe hypoglycemia the lowest one. 
Disutility value for mild hypoglycemic event was 0.012, severe event – 0.085, and 
nocturnal hypoglycemic event – 0.023. cOnclusiOns: The values of health utility 
and disutility for T2DM patients receiving insulin therapy were obtained from the 
real-world data. Severe hypoglycemia was associated with greater disutility than 
non-severe and nocturnal hypoglycemia. The obtained values of health utility and 
